UNICEF Tetanus Diphtheria Market Note 2024 2025 TD Vaccine

A significant involvement of UNICEF offers the procedures & distribution of millions of tetanus and diphtheria vaccines across the globe. Alongside, they focus on facilitating routine immunization programs and maternal and neonatal tetanus elimination (MNTE) campaigns, as well as emergency humanitarian responses. UNICEF has unveiled Td (tetanus-diphtheria) for adolescents and adults, or integrated with pertussis, hepatitis B, and other antigens for children.

UNICEF Td Vaccine Procurement and Supply Chain

UNICEF ensures affordable and uninterrupted Td vaccine access through transparent, competitive tender processes and long-term agreements with qualified manufacturers. These multi-year contracts promote price stability, secure consistent production, and reduce procurement risks for participating countries. Additionally, UNICEF strengthens vaccine availability by managing robust cold-chain logistics and leveraging regional distribution hubs, ensuring timely delivery while maintaining vaccine quality, even in remote, conflict-affected, and resource-limited settings worldwide.

UNICEF's Key Manufacturing Partners

• Serum Institute of India is among UNICEF's largest suppliers, producing WHO-prequalified Td and combination vaccines for global immunization programs.
• Biological E supports UNICEF through affordable Td-containing vaccines and expanded manufacturing capacity.
• Bharat Biotech contributes selected vaccines for international public health initiatives.
• PT Bio Farma supplies WHO-prequalified vaccines across Asia and other regions.
• LG Chem strengthens UNICEF's diversified global vaccine supply network and procurement resilience.

In 2024 & 2025, UNICEF made certain launches, deliveries, such as:

• A rollout of the hexavalent (DTwP-HepB-IPV-Hib) vaccine to bolster protection against diphtheria, tetanus, and other diseases.
• Also, UNICEF fostered the procurement of standard Td (Tetanus-Diphtheria) vaccines at the request of governments for routine childhood immunization & adult booster programs.
• In November 2024, UNICEF delivered 270,000 doses of the Tetanus-Diphtheria (Td) vaccine to Ukraine to ensure continuous booster coverage during consistent grid disruptions.

What are the Major Growth Factors of UNICEF Td Vaccines in 2024 & 2025?

A key driver covers renewed diphtheria outbreaks worldwide, encouraging WHO recommendations to substitute the standalone Tetanus Toxoid (TT) vaccine with the Td vaccine for double protection. Moreover, the emergence of the Big Catch-Up (BCU), propelled by UNICEF, WHO, and Gavi, has massively scaled up catch-up vaccination.  In 2024, an estimated 89% of infants received at least one dose of DTP-containing vaccines, which necessitate sustained supply chains.

Besides this, a late launch of the Gavi DTP booster programme for ages 4-7 and 9-15 kicked off, further rising demand for Td-containing formulations. Alongside, UNICEF has entered into multi-year agreements through 2027, that keeps healthy, stable global production of Td vaccines across over 15 manufacturers.

Regional Demand Trends

Number of DTP Cases received Td Vaccine in 2024 & the Role of UNICEF in these Cases.

• Across the world, nearly 115 million infants (89%) received at least one dose of the diphtheria, tetanus, and pertussis (DTP)-containing vaccine in 2024, along with approximately 109 million (85%) completing all three essential doses. In these cases, UNICEF has been playing a pivotal role, including.
• UNICEF negotiated with manufacturers on behalf of governments and Gavi, the Vaccine Alliance, which projects demand & fuels down vaccine expenditure. Like, UNICEF forecasted the procurement of 217 million doses of the DTwP-HepB-Hib (pentavalent) vaccine for 2024 and roughly 197 million doses for 2025 to spur global demand.
• Also, UNICEF has been targeting communities affected by disputes, institutional fragility, and poverty where children have never gained a single vaccine, i.e., the 14.3 million global zero-dose cases.
• UNICEF manages the delivery, storage, and logistics to ensure vaccines are kept at the proper temperatures (cold chain) even in remote or emerging regions.
• UNICEF supplied vaccines to 100+ countries.
• UNICEF secured Td supply agreements through 2027.
• Emergency Td shipments supported humanitarian responses, including Ukraine.

What Lies Ahead? UNICEF Td Vaccine Outlook for 2026–2027

The UNICEF Td vaccine landscape is expected to witness sustained growth during 2026–2027, supported by expanding Gavi-funded booster programs and continued implementation of the Big Catch-Up initiative. New multi-year procurement agreements are likely to strengthen global supply security while ensuring affordable vaccine access for participating countries. Additionally, digital forecasting and demand-planning systems will enhance procurement accuracy, minimize supply disruptions, and optimize distribution. Greater emphasis on adolescent and adult booster immunization, alongside routine childhood vaccination, is anticipated to improve population immunity, reduce disease outbreaks, and support long-term global immunization goals worldwide.

Conclusion

In the 2024-2025 and current era, the UNICEF is considered a pillar for routine immunizations, outbreak responses, & the global Maternal and Neonatal Tetanus Elimination (MNTE) initiative. Meanwhile, the global market is sustaining as healthy and stable, coupled with UNICEF securing long-term contracts to supply nearly 40% of the global Td vaccine demand through 2027. In 2024 & 2025, about 85% to 89% of infants across the world have received the required 3-dose primary DTP series, with an approximate 14.3 million ‘zero-dose’ children remaining completely unvaccinated, especially impacted in India, Nigeria, & Ethiopia.